JNJ4:27 PMJohnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conferencejnj.com
JNJ8:45 AMJohnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective Septemberjnj.com
JNJ8:30 AMJohnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancerjnj.com
JNJ5:42 PMJohnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovationjnj.com
JNJ5:28 PMJohnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Resetjnj.com
JNJ8:30 AMTECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myelomajnj.com
JNJ7:00 AMJohnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical Systemjnj.com
JNJ8:11 AMJohnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Awardjnj.com
JNJ7:45 AMJohnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platformjnj.com
JNJ12:35 PMJohnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravisPresentation / Abstractjnj.com
JNJ6:00 AMJohnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Floridajnj.com
JNJ6:33 AMNew TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myelomajnj.com
JNJ7:45 AMJohnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patientsjnj.com
JNJ2:03 AMIMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapiesjnj.com
JNJ8:00 AMJohnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platformjnj.com
JNJ12:04 AMJohnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 studyTrial Results • Phase 2jnj.com
JNJ12:03 AMJohnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's diseasejnj.com
JNJ8:29 AMRYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limitedjnj.com
JNJ8:27 AMJohnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigmjnj.com
JNJ2:00 PMRYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancerjnj.com
JNJ8:18 AMNew TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myelomajnj.com
JNJ7:10 PMFDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damagejnj.com